UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Clinical cancer research, 2014-07, Vol.20 (13), p.3446-3457

2014

Volltextzugriff (PDF)

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

Cancer cell, 2018-05, Vol.33 (5), p.890-904.e5

2018

Volltextzugriff (PDF)

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

The lancet oncology, 2021-06, Vol.22 (6), p.883-892

2021

Volltextzugriff (PDF)

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

The lancet oncology, 2017-05, Vol.18 (5), p.599-610

2017

Volltextzugriff (PDF)

Prediction of Clinical Deterioration in Hospitalized Adult Patients with Hematologic Malignancies Using a Neural Network Model

PloS one, 2016-08, Vol.11 (8), p.e0161401-e0161401

2016

Volltextzugriff (PDF)

PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS6113-TPS6113

2024

Volltextzugriff (PDF)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

Molecular cancer, 2014-04, Vol.13 (1), p.83-83, Article 83

2014

Volltextzugriff (PDF)

Targeted Therapy for Melanoma

Cancer treatment and research, 2016, Vol.167, p.251-262

2016

Volltextzugriff (PDF)

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6005-6005

2023

Volltextzugriff (PDF)

Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.6040-6040

2023

Volltextzugriff (PDF)

A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3094-3094

2020

Volltextzugriff (PDF)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Molecular cancer, 2014-08, Vol.13 (1), Article 194

2014

Volltextzugriff (PDF)

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS6089-TPS6089

2021

Volltextzugriff (PDF)

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2652-TPS2652

2019

Volltextzugriff (PDF)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

Molecular cancer, 2015-02, Vol.14 (1), p.27-27, Article 27

2015

Volltextzugriff (PDF)

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e21165-e21165

2023

Volltextzugriff (PDF)

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.679-679

2020

Volltextzugriff (PDF)

A phase II open label, single arm study to evaluate the efficacy of pembrolizumab for leukoplakia

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS10606-TPS10606

2021

Volltextzugriff (PDF)

Estimates of stage-specific preclinical sojourn time across 21 cancer types

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18584-e18584

2021

Volltextzugriff (PDF)

Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.12106-12106

2022

Volltextzugriff (PDF)

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates

Annals of translational medicine, 2014-12, Vol.2 (12), p.122-122

2014

Volltextzugriff (PDF)

Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3083-3083

2020

Volltextzugriff (PDF)

Frailty screening in head and neck cancer care: Implementation outcomes and clinician perspectives

JCO oncology practice, 2023-11, Vol.19 (11_suppl), p.453-453

2023

Volltextzugriff (PDF)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

Molecular cancer, 2012-04, Vol.11 (1), p.22-22, Article 22

2012

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(43)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

Prediction of Clinical Deterioration in Hospitalized Adult Patients with Hematologic Malignancies Using a Neural Network Model

Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

Targeted Therapy for Melanoma

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma

Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC)

A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma

A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

UCLA l-08: A phase ib/II study of combined HER inhibition adding necitumumab and trastuzumab to osimertinib in patients with refractory EGFR-mutated lung cancer

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study

A phase II open label, single arm study to evaluate the efficacy of pembrolizumab for leukoplakia

Estimates of stage-specific preclinical sojourn time across 21 cancer types

Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates

Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism

Frailty screening in head and neck cancer care: Implementation outcomes and clinician perspectives

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

Suchergebnisse filtern